港股博安生物瞬间飙升超200%，成交额放大至2亿港元！华安证券：构建符合中、美、欧GMP标准的生产体系

格隆汇2025-04-17

格隆汇4月17日｜博安生物尾盘拉升，一度飙涨203%至25港元，成交额放大至2亿港元。华安证券近日发研报称，博安生物在生物类似药领域展现出显著的稳定创收能力与国际化布局优势。公司已在国内获批贝伐珠单抗和两款地舒单抗(BA6101和BA1102)生物类似药，同时该两款地舒单抗的欧、美、日国际多中心Ⅲ期临床试验于2024年1月完成所有受试者入组，计划覆盖全球市场并在海外核心市场进行授权合作。度拉糖肽（...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2528191768?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-17 15:47","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2528191768","market":"hk","top_or_hot":-1,"title":"港股博安生物瞬间飙升超200%，成交额放大至2亿港元！华安证券：构建符合中、美、欧GMP标准的生产体系","media":"格隆汇","content":"<div>\n<p>格隆汇4月17日｜博安生物尾盘拉升，一度飙涨203%至25港元，成交额放大至2亿港元。华安证券近日发研报称，博安生物在生物类似药领域展现出显著的稳定创收能力与国际化布局优势。公司已在国内获批贝伐珠单抗和两款地舒单抗(BA6101和BA1102)生物类似药，同时该两款地舒单抗的欧、美、日国际多中心Ⅲ期临床试验于2024年1月完成所有受试者入组，计划覆盖全球市场并在海外核心市场进行授权合作。度拉糖肽（...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041715522694d87256&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股博安生物瞬间飙升超200%，成交额放大至2亿港元！华安证券：构建符合中、美、欧GMP标准的生产体系</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股博安生物瞬间飙升超200%，成交额放大至2亿港元！华安证券：构建符合中、美、欧GMP标准的生产体系\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-17 15:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041715522694d87256&s=b><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇4月17日｜博安生物尾盘拉升，一度飙涨203%至25港元，成交额放大至2亿港元。华安证券近日发研报称，博安生物在生物类似药领域展现出显著的稳定创收能力与国际化布局优势。公司已在国内获批贝伐珠单抗和两款地舒单抗(BA6101和BA1102)生物类似药，同时该两款地舒单抗的欧、美、日国际多中心Ⅲ期临床试验于2024年1月完成所有受试者入组，计划覆盖全球市场并在海外核心市场进行授权合作。度拉糖肽（...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041715522694d87256&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSTECH","symbol_name":"恒生科技指数","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041715522694d87256&s=b","article_id":"2528191768","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041715522694d87256&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2528191768","pubTimestamp":1744876071,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"格隆汇4月17日｜博安生物尾盘拉升，一度飙涨203%至25港元，成交额放大至2亿港元。华安证券近日发研报称，博安生物在生物类似药领域展现出显著的稳定创收能力与国际化布局优势。通过构建符合中、美、欧GMP标准的生产体系，博安生物成功推动地舒单抗等产品抢占原研药专利到期的市场窗口期，使biosimilar业务成为公司盈利的基础驱动力。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HSTECH":"恒生科技指数","BK1161":"生物科技","06955":"博安生物"},"translate_title":"The Hong Kong stock Boan Biotech soared by more than 200% in an instant, and the turnover enlarged to HK $200 million! Huaan Securities: Build a production system that meets the GMP standards of China, the United States and Europe","themeId":"b4337be690eea1ebb39fed823b4450d5","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HSTECH":1,"06955":1},"content_text":"格隆汇4月17日｜博安生物尾盘拉升，一度飙涨203%至25港元，成交额放大至2亿港元。华安证券近日发研报称，博安生物在生物类似药领域展现出显著的稳定创收能力与国际化布局优势。公司已在国内获批贝伐珠单抗和两款地舒单抗(BA6101和BA1102)生物类似药，同时该两款地舒单抗的欧、美、日国际多中心Ⅲ期临床试验于2024年1月完成所有受试者入组，计划覆盖全球市场并在海外核心市场进行授权合作。度拉糖肽（BA5101）和阿柏西普（BA9101）生物类似药在国内处于BLA审评阶段，且前者在美国获批临床，研发进度在同类产品中领先。通过构建符合中、美、欧GMP标准的生产体系（商业化产能达9000L），博安生物成功推动地舒单抗等产品抢占原研药专利到期的市场窗口期，使biosimilar业务成为公司盈利的基础驱动力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2528191768","isCrawlerRequest":true}